Movatterモバイル変換


[0]ホーム

URL:


IN2012DN00352A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00352A
IN2012DN00352AIN352DEN2012AIN2012DN00352AIN 2012DN00352 AIN2012DN00352 AIN 2012DN00352AIN 352DEN2012 AIN352DEN2012 AIN 352DEN2012AIN 2012DN00352 AIN2012DN00352 AIN 2012DN00352A
Authority
IN
India
Prior art keywords
compounds
methods
opsin proteins
compositions
mislocalization
Prior art date
Application number
Inventor
David S Garvey
Gregory J Larosa
Jeremy Robert Greenwood
Tan Quach
Jamie B Cote
Judd Berman
Mark L Brewer
Original Assignee
Bikam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bikam Pharmaceuticals IncfiledCriticalBikam Pharmaceuticals Inc
Publication of IN2012DN00352ApublicationCriticalpatent/IN2012DN00352A/en

Links

Classifications

Landscapes

Abstract

Compounds and compositions of said compounds along with methods of use of compounds are disclosed for treating ophthalmic conditions related to mislocalization of opsin proteins, the misfolding of mutant opsin proteins and the production of toxic visual cycle products that accumulate in the eye. Compounds and compositions useful in the these methods, either alone or in combination with other therapeutic agents, are also described.
IN352DEN20122009-06-162010-01-21IN2012DN00352A (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US26875709P2009-06-162009-06-16
PCT/US2010/001739WO2010147653A1 (en)2009-06-162010-06-16Opsin-binding ligands, compositions and methods of use

Publications (1)

Publication NumberPublication Date
IN2012DN00352Atrue IN2012DN00352A (en)2015-08-21

Family

ID=43356669

Family Applications (1)

Application NumberTitlePriority DateFiling Date
IN352DEN2012IN2012DN00352A (en)2009-06-162010-01-21

Country Status (20)

CountryLink
US (2)US9562022B2 (en)
EP (2)EP3100723B1 (en)
KR (3)KR101726358B1 (en)
CN (1)CN102480943A (en)
AU (1)AU2010260535B2 (en)
CA (1)CA2767895C (en)
CY (1)CY1118221T1 (en)
DK (1)DK2442644T3 (en)
EA (1)EA021747B1 (en)
ES (1)ES2610429T3 (en)
HR (1)HRP20161477T1 (en)
HU (1)HUE031705T2 (en)
IN (1)IN2012DN00352A (en)
LT (1)LT2442644T (en)
PL (1)PL2442644T3 (en)
PT (1)PT2442644T (en)
SI (1)SI2442644T1 (en)
SM (2)SMT201600388T1 (en)
WO (1)WO2010147653A1 (en)
ZA (1)ZA201200226B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
AU2007277032A1 (en)*2006-07-272008-01-31University Of Florida Research Foundation, Inc.Opsin stabilizing compounds and methods of use
IN2012DN00352A (en)2009-06-162015-08-21Bikam Pharmaceuticals Inc
WO2012134971A2 (en)*2011-03-252012-10-04Bikam Pharmaceuticals, Inc.Opsin-binding ligands, compositions and methods of use
WO2012174064A1 (en)2011-06-142012-12-20Bikam Pharmaceuticals, Inc.Opsin-binding ligands, compositions and methods of use
AU2012325341B2 (en)2011-10-192017-01-05Bikam Pharmaceuticals, Inc.Opsin-binding ligands, compositions and methods of use
BR112014012997A2 (en)*2011-11-302017-06-13Bikam Pharmaceuticals Inc opsin binding binders, compositions and methods of use
WO2013081642A1 (en)*2011-12-012013-06-06Bikam Pharmaceuticals, Inc.Opsin-binding ligands, compositions and methods of use
US9023883B2 (en)2013-03-142015-05-05Epizyme, Inc.PRMT1 inhibitors and uses thereof
US9120757B2 (en)2013-03-142015-09-01Epizyme, Inc.Arginine methyltransferase inhibitors and uses thereof
WO2014153214A1 (en)2013-03-142014-09-25Epizyme, Inc.Arginine methyl transferase inhibtors and uses thereof
US9765035B2 (en)2013-03-142017-09-19Epizyme, Inc.Arginine methyltransferase inhibitors and uses thereof
JP2016514164A (en)2013-03-142016-05-19エピザイム,インコーポレイティド Pyrazole derivatives and their use as arginine methyltransferase inhibitors
EP2970133B1 (en)2013-03-142018-10-24Epizyme, Inc.Pyrazole derivatives as prmt1 inhibitors and uses thereof
KR102028793B1 (en)2013-03-142019-10-07에피자임, 인코포레이티드Arginine methyl transferase inhibitors and uses thereof
CA2942386A1 (en)2014-03-132015-09-17Proteostasis Therapeutics, Inc.Compounds, compositions, and methods for increasing cftr activity
CA2942387A1 (en)2014-03-132015-09-17Proteostasis Therapeutics, Inc.Compounds, compositions and methods of increasing cftr actvity
CA2952862A1 (en)2014-06-192015-12-23Proteostasis Therapeutics, Inc.Compounds, compositions and methods of increasing cftr activity
US10738011B2 (en)2014-12-232020-08-11Proteostasis Therapeutics, Inc.Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10392378B2 (en)2014-12-232019-08-27Proteostasis Therapeutics, Inc.Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10344023B2 (en)2014-12-232019-07-09Proteostasis Therapeutics, Inc.Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
MA41253A (en)2014-12-232017-10-31Proteostasis Therapeutics Inc COMPOUNDS, COMPOSITIONS AND PROCESSES TO INCREASE THE ACTIVITY OF CFTR
MA42488A (en)2015-07-242018-05-30Proteostasis Therapeutics Inc COMPOUNDS, COMPOSITIONS AND PROCESSES TO INCREASE THE ACTIVITY OF CFTR
EP3359536B1 (en)2015-10-062021-08-04Proteostasis Therapeutics, Inc.Compounds, compositions, and methods for modulating cftr
WO2017177124A1 (en)2016-04-072017-10-12Proteostasis Therapeutics, Inc.Silicone atoms containing ivacaftor analogues
WO2017223188A1 (en)2016-06-212017-12-28Proteostasis Therapeutics, Inc.Compounds, compositions, and methods for increasing cftr activity
JOP20190245A1 (en)2017-04-202019-10-15Novartis AgSustained release delivery systems comprising traceless linkers
JP7157072B2 (en)*2017-10-162022-10-19高砂香料工業株式会社 Cooling agent composition containing 2,2,6-trimethylcyclohexanecarboxylic acid derivative
AR116566A1 (en)2018-10-032021-05-19Novartis Ag SUSTAINED ADMINISTRATION OF ANGIOPOYETIN-SIMILAR POLIPEPTIDES 3
EP4183449A1 (en)2021-11-172023-05-24Samsara Therapeutics Inc.Autophagy inducing compounds and uses thereof

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3022291A (en)*1962-02-20cuhno
US3416530A (en)1966-03-021968-12-17Richard A. NessEyeball medication dispensing tablet
US3854480A (en)1969-04-011974-12-17Alza CorpDrug-delivery system
US3773919A (en)1969-10-231973-11-20Du PontPolylactide-drug mixtures
BE764656A (en)*1970-03-251971-09-22Fujisawa Pharmaceutical Co NEW QUATERNARY AMMONIUM SALTS AND THEIR APPLICATION TO THE REGULATION OF PLANT GROWTH
US3828777A (en)1971-11-081974-08-13Alza CorpMicroporous ocular device
BE802469A (en)*1972-07-201974-01-18Wilkinson Sword Ltd IMPROVEMENTS MADE AND / OR RELATING TO COMPOUNDS EXERCISING A PHYSIOLOGICAL REFRIGERANT EFFECT AND COMPOSITIONS CONTAINING THEM
US3832253A (en)1973-03-211974-08-27Baxter Laboratories IncMethod of making an inflatable balloon catheter
US4014335A (en)1975-04-211977-03-29Alza CorporationOcular drug delivery device
US4244890A (en)1977-12-141981-01-13Scm CorporationCyclic terpenoid amines, their preparation and uses
US4263428A (en)1978-03-241981-04-21The Regents Of The University Of CaliforniaBis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE2830764A1 (en)1978-07-131980-01-31Basf Ag ACETANILIDE
US4300557A (en)1980-01-071981-11-17The United States Of America As Represented By The Secretary Of The Department Of Health And Human ServicesMethod for treating intraocular malignancies
EP0052322B1 (en)1980-11-101985-03-27Gersonde, Klaus, Prof. Dr.Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
US4327725A (en)1980-11-251982-05-04Alza CorporationOsmotic device with hydrogel driving member
IE52535B1 (en)1981-02-161987-12-09Ici PlcContinuous release pharmaceutical compositions
US4485045A (en)1981-07-061984-11-27Research CorporationSynthetic phosphatidyl cholines useful in forming liposomes
DE3374837D1 (en)1982-02-171988-01-21Ciba Geigy AgLipids in the aqueous phase
DE3218121A1 (en)1982-05-141983-11-17Leskovar, Peter, Dr.-Ing., 8000 MünchenPharmaceutical compositions for tumour treatment
US4667014A (en)1983-03-071987-05-19Syntex (U.S.A.) Inc.Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
EP0102324A3 (en)1982-07-291984-11-07Ciba-Geigy AgLipids and surfactants in an aqueous medium
US4452775A (en)1982-12-031984-06-05Syntex (U.S.A.) Inc.Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en)1983-05-131986-02-11Societe Des Produits Nestle S.A.Food process
US4544545A (en)1983-06-201985-10-01Trustees University Of MassachusettsLiposomes containing modified cholesterol for organ targeting
HUT35524A (en)1983-08-021985-07-29Hoechst AgProcess for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
ATE59966T1 (en)1983-09-261991-02-15Ehrenfeld Udo MEDICATION AND PRODUCT FOR THE DIAGNOSIS AND THERAPY OF TUMORS AND FOR THE TREATMENT OF WEAKNESSES IN THE CELLULAR AND HUMORAL IMMUNE DEFENSE.
US4615885A (en)1983-11-011986-10-07Terumo Kabushiki KaishaPharmaceutical composition containing urokinase
EP0177742B1 (en)1984-09-121990-03-07Firmenich SaNitrogen compounds, their preparation and their use as starting products for the preparation of decalin ketones
US5147647A (en)1986-10-021992-09-15Sohrab DarougarOcular insert for the fornix
US5322691A (en)1986-10-021994-06-21Sohrab DarougarOcular insert with anchoring protrusions
US5075109A (en)1986-10-241991-12-24Southern Research InstituteMethod of potentiating an immune response
US4997652A (en)1987-12-221991-03-05VisionexBiodegradable ocular implants
US4853224A (en)1987-12-221989-08-01VisionexBiodegradable ocular implants
US4894388A (en)1988-12-221990-01-16Monsanto CompanyGlycosidase inhibitors and use thereof
DE3905050A1 (en)1989-02-181990-08-30Lohmann Therapie Syst Lts THERAPEUTIC SYSTEM FOR DELAYED AND CONTROLLED TRANSDERMAL OR TRANSMUCOSAL ADMINISTRATION OF ACTIVE SUBSTANCES (II)
US4946450A (en)1989-04-181990-08-07Biosource Genetics CorporationGlucan/collagen therapeutic eye shields
US5103008A (en)1989-08-171992-04-07Monsanto CompanyCompound, N-butyl-deoxynojirimycin-6-phosphate
US5043273A (en)1989-08-171991-08-27Monsanto CompanyPhosphorylated glycosidase inhibitor prodrugs
US5164188A (en)1989-11-221992-11-17Visionex, Inc.Biodegradable ocular implants
JPH04167172A (en)1990-10-311992-06-15Nec CorpVector processor
US5290892A (en)1990-11-071994-03-01Nestle S.A.Flexible intraocular lenses made from high refractive index polymers
US5378475A (en)1991-02-211995-01-03University Of Kentucky Research FoundationSustained release drug delivery devices
US5679666A (en)1991-11-221997-10-21Alcon Laboratories, Inc.Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
US5770592A (en)1991-11-221998-06-23Alcon Laboratories, Inc.Prevention and treatment of ocular neovascularization using angiostatic steroids
US5178635A (en)1992-05-041993-01-12Allergan, Inc.Method for determining amount of medication in an implantable device
FR2690846B1 (en)1992-05-051995-07-07Aiache Jean Marc GALENIC FORM FOR EYE ADMINISTRATION AND METHOD OF PREPARATION.
US5672659A (en)1993-01-061997-09-30Kinerton LimitedIonic molecular conjugates of biodegradable polyesters and bioactive polypeptides
WO1995003009A1 (en)1993-07-221995-02-02Oculex Pharmaceuticals, Inc.Method of treatment of macular degeneration
US5443505A (en)1993-11-151995-08-22Oculex Pharmaceuticals, Inc.Biocompatible ocular implants
US5455351A (en)1993-12-131995-10-03Abbott LaboratoriesRetroviral protease inhibiting piperazine compounds
US5516522A (en)1994-03-141996-05-14Board Of Supervisors Of Louisiana State UniversityBiodegradable porous device for long-term drug delivery with constant rate release and method of making the same
WO1995024929A2 (en)1994-03-151995-09-21Brown University Research FoundationPolymeric gene delivery system
US5710165A (en)1994-07-061998-01-20SynthelaboUse of polyamine antagonists for the treatment of glaucoma
US5844102A (en)1994-07-071998-12-01University Of Maryland Baltimore CountyGlycohydrolase inhibitors, their preparation and use thereof
US5595760A (en)1994-09-021997-01-21DelabSustained release of peptides from pharmaceutical compositions
AUPM897594A0 (en)1994-10-251994-11-17Daratech Pty LtdControlled release container
ATE232089T1 (en)1994-11-102003-02-15Univ Kentucky Res Found CONTROLLED RELEASE IMPLANTABLE REFILLABLE DEVICE FOR ADMINISTERING DRUGS IMMEDIATELY TO AN INTERNAL PART OF THE BODY
US5725493A (en)1994-12-121998-03-10Avery; Robert LoganIntravitreal medicine delivery
US5869079A (en)1995-06-021999-02-09Oculex Pharmaceuticals, Inc.Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5773019A (en)1995-09-271998-06-30The University Of Kentucky Research FoundationImplantable controlled release device to deliver drugs directly to an internal portion of the body
US5743274A (en)1996-03-181998-04-28Peyman; Gholam A.Macular bandage for use in the treatment of subretinal neovascular members
US5824073A (en)1996-03-181998-10-20Peyman; Gholam A.Macular indentor for use in the treatment of subretinal neovascular membranes
US5904144A (en)1996-03-221999-05-18Cytotherapeutics, Inc.Method for treating ophthalmic diseases
US6299895B1 (en)1997-03-242001-10-09Neurotech S.A.Device and method for treating ophthalmic diseases
AU734905B2 (en)1996-04-102001-06-28Regents Of The University Of California, TheCorrection of genetic defects using chemical chaperones
US6270954B1 (en)1996-04-102001-08-07The Regents Of The University Of CaliforniaCorrection of genetic defects using chemical chaperones
AU6319196A (en)*1996-07-051998-02-02Shionogi & Co., Ltd.P/q type calcium channel antagonist
DE19638486A1 (en)1996-09-201998-03-26Basf Ag Hetaroyl derivatives
DE69827138T2 (en)1997-08-112006-02-23Allergan, Inc., Irvine Sterile retinoid-containing biodegradable implant with improved biocompatibility and process for its preparation
US5902598A (en)1997-08-281999-05-11Control Delivery Systems, Inc.Sustained release drug delivery devices
US6146366A (en)1998-11-032000-11-14Ras Holding CorpDevice for the treatment of macular degeneration and other eye disorders
US6492333B1 (en)1999-04-092002-12-10Osteoscreen, Inc.Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6562836B1 (en)1999-05-242003-05-13Queen's University Of KingstonMethods and compounds for inhibiting amyloid deposits
US6416777B1 (en)1999-10-212002-07-09Alcon Universal Ltd.Ophthalmic drug delivery device
US6331313B1 (en)1999-10-222001-12-18Oculex Pharmaceticals, Inc.Controlled-release biocompatible ocular drug delivery implant devices and methods
NZ519183A (en)*1999-12-032005-02-25Ono Pharmaceutical CoTriazaspiro[5.5]undecane derivatives and pharmaceutical compositions comprising thereof, as an active ingredient
US6656912B2 (en)2000-01-202003-12-02Washington University In St. LouisMethods to treat α1-antitrypsin deficiency
EP1181277A4 (en)2000-03-312005-08-10Univ Michigan State PROCESS FOR THE PREPARATION OF 1,5-DIDEOXY-1,5-IMINO-HEXITOLES FROM OXIMES OR IMINES
US6375972B1 (en)2000-04-262002-04-23Control Delivery Systems, Inc.Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US6818203B2 (en)*2000-08-112004-11-16Schering AktiengesellschaftUse of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses
CA2432203C (en)2001-01-032008-03-25Michael J. BrubakerSustained release drug delivery devices with multiple agents
GB0118752D0 (en)2001-08-012001-09-26Pfizer LtdProcess for the production of quinazolines
EP1430042A2 (en)2001-09-252004-06-23SmithKline Beecham CorporationBicyclic heterocycles as rxr ligands
US6976584B2 (en)2002-06-262005-12-20Bausch & Lomb IncorporatedPackage for surgical implant
US20040131648A1 (en)*2002-10-242004-07-08The Procter & Gamble CompanyNuclear hormone receptor compounds, products and methods employing same
US20050048099A1 (en)2003-01-092005-03-03Allergan, Inc.Ocular implant made by a double extrusion process
BRPI0407001A (en)2003-01-312006-01-10Sinai School Medicine Method for increasing the stability of a purified protein, use of a site-specific active binding protein, method for increasing the production of a recombinant protein and pharmaceutical composition
EP2327400A3 (en)2003-03-142011-10-19University of WashingtonRetinoid Replacements and Opsin Agonists and Methods for the Use Thereof
WO2004108867A2 (en)2003-06-022004-12-16Flexitral, Inc.Cyclohexene carboamides and carbothioamides
CL2004001996A1 (en)2003-08-082005-05-06Eyetech Pharmaceuticals Inc ANTI-VEGF APTAMEROS (VASCULAR ENDOTELIAL GROWTH FACTOR) WITH 5'-5 'OR 3'-3' INVERTED NUCLEOTIDIC BLOCK, COMPOSITION CONTAINING IT, USEFUL FOR NEOVASCULARIZATION DISORDERS.
NZ550340A (en)2004-03-172010-08-27Lars Michael LarsenPrevention of retinopathy by inhibition of the visual cycle using a retinoid
KR20140140616A (en)2004-06-182014-12-09유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션Retinal derivatives and methods for the use thereof for the treatment of visual disorders
MXPA06014978A (en)2004-06-232007-04-25Sirion Therapeutics IncMethods and compositions for treating ophthalmic conditions with retinyl derivatives.
WO2006033734A2 (en)2004-08-182006-03-30Sirion Therapeutics, Inc.Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
WO2006039551A2 (en)2004-09-302006-04-13The Regents Of The University Of CaliforniaLocal administration of retinoids to treat deficiencies in dark adaptation
US8946444B2 (en)2004-11-232015-02-03Ptc Therapeutics, Inc.Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control
CA2642927A1 (en)2005-02-242006-08-31University Of WashingtonMethods for treatment of retinal degenerative disease
GB0506133D0 (en)*2005-03-242005-05-04Sterix LtdCompound
KR20080072721A (en)2005-11-302008-08-06이노텍 파마슈티컬스 코포레이션 Purine derivatives and methods of use thereof
AU2007277033A1 (en)*2006-07-272008-01-31University Of Florida Research Foundation, Inc.Compositions and methods for treating or preventing ophthalmic disease
AU2007277035A1 (en)2006-07-272008-01-31University Of Florida Research Foundation, Inc.Compositions and methods for treating or preventing ophthalmic light toxicity
AU2007277032A1 (en)2006-07-272008-01-31University Of Florida Research Foundation, Inc.Opsin stabilizing compounds and methods of use
JP5592265B2 (en)2007-11-012014-09-17アキュセラ インコーポレイテッド Amine derivative compounds for the treatment of eye diseases and disorders
US8642660B2 (en)*2007-12-212014-02-04The University Of RochesterMethod for altering the lifespan of eukaryotic organisms
US20110015442A1 (en)2008-03-172011-01-20Toshiya TakahashiSulfone compound and method for producing the same
AU2009308483C1 (en)2008-10-222014-01-23Acucela, Inc.Compounds for treating ophthalmic diseases and disorders
WO2010074746A1 (en)2008-12-232010-07-01Bikam Pharmaceuticals, Inc.Methods of use for opsin binding ligands
IN2012DN00352A (en)2009-06-162015-08-21Bikam Pharmaceuticals Inc
WO2012174064A1 (en)2011-06-142012-12-20Bikam Pharmaceuticals, Inc.Opsin-binding ligands, compositions and methods of use

Also Published As

Publication numberPublication date
KR101921288B1 (en)2018-11-22
EP2442644B1 (en)2016-08-10
SMT201600388B (en)2017-03-08
CA2767895A1 (en)2010-12-23
AU2010260535A1 (en)2012-02-02
PL2442644T3 (en)2017-02-28
US9562022B2 (en)2017-02-07
EP3100723B1 (en)2019-06-12
CA2767895C (en)2017-12-12
HRP20161477T1 (en)2016-12-16
EA021747B1 (en)2015-08-31
AU2010260535B2 (en)2015-08-20
KR20120112351A (en)2012-10-11
CN102480943A (en)2012-05-30
DK2442644T3 (en)2016-10-10
EA201270018A1 (en)2012-07-30
WO2010147653A1 (en)2010-12-23
EP2442644A4 (en)2013-05-22
EP3100723A1 (en)2016-12-07
US20110003784A1 (en)2011-01-06
EP2442644A1 (en)2012-04-25
US20170037018A1 (en)2017-02-09
KR101726358B1 (en)2017-04-26
SI2442644T1 (en)2017-01-31
SMT201600388T1 (en)2017-03-08
KR20170041282A (en)2017-04-14
PT2442644T (en)2016-11-09
HUE031705T2 (en)2017-07-28
ZA201200226B (en)2013-06-26
CY1118221T1 (en)2017-06-28
LT2442644T (en)2016-12-12
KR20180099944A (en)2018-09-05
ES2610429T3 (en)2017-04-27

Similar Documents

PublicationPublication DateTitle
IN2012DN00352A (en)
IN2015DN01156A (en)
MX2011009539A (en)Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof.
PH12014500767A1 (en)Compositions for the treatment of dry eye
IN2012DN03312A (en)
AU2012253759A8 (en)Tricyclic sulfonamide compounds and methods of making and using same
NZ709392A (en)Synergistic bacterial compositions and methods of production and use thereof
MX2013005549A (en)Heterocycle amines and uses thereof.
NZ727304A (en)Compositions and methods of use of phorbol esters for the treatment of stroke
IN2012DN00624A (en)
AU2011328009A8 (en)Compounds and methods for treating pain
MX351464B (en)Methods for the treatment of allergic diseases.
MX344238B (en)Tetrazole compounds and methods of making and using same.
PH12013501490A1 (en)Methods for diagnosing and treating eye-length related disorders
AU2012253757A8 (en)Partially saturated tricyclic compounds and methods of making and using same
IN2012DN02645A (en)
MX2016007711A (en)Modified serpins for the treatment of bleeding disorders.
IN2015DN01151A (en)
MX356755B (en)Fumigillol type compounds and methods of making and using same.
WO2013022740A3 (en)Gpr35 ligands and the uses thereof
BRPI0917245A8 (en) ISOQUINOLINONE DERIVATIVE COMPOUNDS AND THEIR PHARMACEUTICAL COMPOSITION
GB201213484D0 (en)Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
MX2016000294A (en)Pharmaceutical composition for a sustained release of lanreotide.
MY191337A (en)Compositions for the treatment of hypertension and/or fibrosis
BR112012015449A2 (en) calcipotriol monohydrate suspension, calcipotriol monohydrate, process for preparing calcipotriol monohydrate nanocrystals, and, pharmaceutical composition

[8]ページ先頭

©2009-2025 Movatter.jp